Glycemicon
Br├╝gg
About Glycemicon
Glycemicon AG is a Swiss biotechnology company developing novel nutraceuticals for managing prediabetes, diabetes and obesity, using new approaches that were initially developed at the University of Science & Technology ETH Zurich. The lead product’s active substance is a naturally-occurring bile acid, THBA, which drives changes to the body fat architecture that combat elevated blood glucose levels. Glycemicon stands for "glycemic control" - the maintenance of healthy blood sugar levels, which is the aim of every individual living with prediabetes and diabetes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $5.3M
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2018)
- Website: glycemicon.com
- Phone: +41 56 560 50 20
Industries & Categories
Biotechnology, Nutraceutical
Social Profiles
Canonical: https://fsome.com/organization/glycemicon-17226 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.